Skip to content

Peginterferon(PEG-IFN) alfa-2a in chronic hepatitis B patients without nucleos(t)ide analogues (NA) treatment

Peginterferon(PEG-IFN) alfa-2a in chronic hepatitis B patients without nucleos(t)ide analogues (NA) treatment - PEG-IFN for CH-B

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000007946
Enrollment
100
Registered
2012-05-14
Start date
2012-05-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients infected with hepatitis B virus

Interventions

None listed

Sponsors

Chiba University, Graduate School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients were eligible if they met the following inclusion criteria: (i) infected with HBV alone, (ii) age =>20 years, (iii) diagnosed as chronic hepatitis B, (iv) WBC =>3000/mm3 , (v) neutrophils =>1500/mm3, (vi) platelets =>90000/mm3, (vii) hemoglobin => 12 g/dL, (viii) Doctors judged patient as appropriate person in this trial, (ix)HBV DNA-positive patients, (x)no or mild hepatic fibrosis, (xi) patient and his/her family underst and well this disease and treatment.

Exclusion criteria

Exclusion criteria: 1) Pregnancy 2) Severe liver diseases 3) Cirrhosis or hepatic failure such as chronic liver diseases, e.g. autoimmune hepatitis and alcoholic hepatitis 4) Severe other diseases 5) History of pneumonitis 6) Past-history of hypersensitivity against interferon or peginterferon, etc. 7) Severe mental disorders 8) Abnormal hematological exams 9) Past-history of hypersensitivity against vaccination, etc. 10) Under treatment of TJ-9 11) Doctor judged patient as inappropriate person in this trial

Design outcomes

Primary

MeasureTime frame
HBV DNA and ALT levels at 24 week after stopping the treatment

Countries

Japan

Contacts

Public ContactTatsuo Kanda, M.D.

Chiba University, Graduate School of Medicine Department of Gastroenterology and Nephrology

kandat-cib@umin.ac.jp0432262086

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026